Evommune terminates oral drug’s development in CSU

While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue. While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue. The drug failed to show any benefit in CSU patients in a Phase IIb trial. Credit: FON’s Fasai / Shutterstock.com Evommune’s oral MRGPRX2 antagonist has failed to show benefit in patients with chronic spontaneous urticaria (CSU). In a Phase IIb study (NCT06873516), EVO756 failed to meet its primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7)…

Source: Clinical Trials Arena